Sep 9, 2026Solstice was founded in February and quickly licensed porustobart from Harbour BioMed for development and commercialization outside of China under a deal that included a $105 million upfront package. Its financing now funds a phase 2 trial in a patient population the company says has yet to benefit from immunotherapy, with enrollment due to begin this year or in the fourth quarter depending on the source and data expected in the second half of 2027.
The Catalyst Brief
Sep 9, 2026BioSpace reports that crossover rounds began picking up around the fourth quarter of 2025, before the current IPO boom became obvious. The pattern suggests public investors did not abandon biotech during the downturn; instead, they accepted longer timelines and are now helping restock the listing pipeline as the market reopens.
The Catalyst Brief
Sep 9, 2026Moonwalk is positioning MW101 as a long-lasting RNAi-based obesity candidate after preclinical mouse data showed weight loss and fat reduction while maintaining muscle mass without reducing food intake. The round adds to a $57 million seed launch in early 2024 and highlights continued investor interest in differentiated metabolic programs despite a market dominated by GLP-1 drugs.
The Catalyst Brief
Sep 8, 2026The financing gives the Seattle Children’s Hospital spinout enough capital to continue its lead effort in diffuse intrinsic pontine glioma, or DIPG, where BrainChild is running an open-label, single-arm phase 2 study of BCB-276. Across the available reporting, the raise is described as $116 million by Fierce Biotech and $119 million by BioSpace, a discrepancy the company’s sourced coverage does not resolve.
The Catalyst Brief
Sep 7, 2026ADARx Pharmaceuticals is seeking fresh public-market capital despite entering 2026 with $427.3 million in cash, using the offering to support a wide clinical agenda across complement, hereditary angioedema and thrombosis-related programs. The move adds to this year's biotech IPO wave while showing that investors are again being asked to fund platform breadth, not just a single lead asset.
The Catalyst Brief
Sep 6, 2026The latest Drive cohorts bring together companies working across small molecules, antibodies, gene editing, gene therapy, oncolytic viruses and cell therapy. For a market where the earliest financing remains hard to raise, the program is functioning less as publicity and more as infrastructure to help companies reach the next financing or development milestone.
The Catalyst Brief
Sep 4, 2026A Truist Securities note points to broad recovery signals across biotech, from IPOs and venture funding to large-cap acquisitions driven by patent cliffs. The firm also said regulatory and policy risks have largely played out, with innovation again driving stock performance.
The Catalyst Brief
Sep 2, 2026By Leerink’s count, biopharma has seen 20 IPOs and 19 reverse mergers in 2026 so far, with 17 reverse mergers already completed or planned to close this quarter. The pattern suggests private companies are increasingly running multiple financing paths in parallel rather than waiting on a single IPO window.
The Catalyst Brief
Sep 1, 2026The company plans to list on the Nasdaq Global Select Market under the symbol ETRA and use proceeds to support its immunology and cancer pipeline. Most of the strategic weight sits on ipsoprubart, a monoclonal antibody already in a global phase 2/3 trial and positioned for a potential biologics license application and commercial readiness work.
The Catalyst Brief
Aug 29, 2026The financing comes after AusperBio had already raised $37 million in series A in 2024 and a three-part series B across 2024-25 totaling $186 million. For investors, the signal is that capital is still available for hepatitis B programs that can pair late-stage momentum with a broader oligonucleotide platform story.
The Catalyst Brief
Aug 28, 2026Roche’s Genentech is licensing access to DualityBio’s Dupac payload platform as more patients receive first-line antibody-drug conjugates such as Enhertu and Trodelvy and then progress. DualityBio will take candidates into the clinic before Genentech assumes sole responsibility for development after phase 1a, combining Genentech’s portfolio reach with China-based early-stage development economics.
The Catalyst Brief
Aug 27, 2026Someit Sidhu has brought a third biotech-focused SPAC to market just two months after pairing JATT II with Talawar Therapeutics. The new vehicle is targeting data-driven life sciences businesses, highlighting that even in a cooler SPAC market, sponsors still see openings around platform-heavy biotech stories.
The Catalyst Brief
